Pharmaceuticals


9
May 14

EirGen Pharma to Create 40 Jobs for South-east Ireland

EirGen Pharma to create 40 jobs for south-east IrelandIrish pharmaceutical company EirGen Pharma is to create 40 jobs for highly skilled graduates and experienced professionals on the back of opening its international headquarters in Waterford.

EirGen Pharma has made a €4m investment in a state-of-the-art high-containment facility, enabling the company to specialise in the development, registration and manufacture of oncology products for global markets.

“We are delighted to be making this significant jobs announcement,” said Patsy Carney, CEO of EirGen Pharma.

“Since EirGen’s inception, we have been committed to high-tech job creation for the south-east.”

The life-sciences sector is the fastest-growing area of Ireland’s export industry, added Tom Brennan, chief technical officer.

“We hope that our continuing efforts will inspire other high-end technology companies to invest – and re-invest – in the region, providing further opportunities for employment growth while driving forward efforts to secure Ireland’s future as the location-of-choice for world-leading, research and manufacturing industries,” Brennan said.

Read [+]

 

  • Facebook
  • Twitter
  • LinkedIn
  • Google Bookmarks
  • Share/Bookmark

2
May 14

Pharmaceutical Firm BioMarin Manufacturing Ireland Creating 50 Dublin Jobs

BioMarin Pharmaceutical is expanding its Dublin operationBioMarin Manufacturing Ireland, a subsidiary of BioMarin Pharmaceutical Inc, is to add the positions at its Dublin Global Commercial Operations Hub.

The expansion follows the announcement earlier this week that the European Commission had approved VIMIZIM, an enzyme replacement drug made by BioMarin.

The jobs will be in accounting, finance, customer service and marketing.

The Dublin operation has responsibility for international supply chain, logistics and high-level commercial decision making, including price, distribution and third party contracts for the launch of VIMIZIM.

BioMarin also has a biopharma manufacturing facility in Shanbally in Co Cork, which is expected to grow to 140 employees by 2015.

The investment is supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland.

Minister for Jobs, Enterprise and Innovation Richard Bruton said the announcement was a further boost for the sector and for the city.

BioMarin Vice-President James Lennertz described Ireland as an ideal business environment and said Dublin was an essential part of the company’s strategy.

Read [+]

  • Facebook
  • Twitter
  • LinkedIn
  • Google Bookmarks
  • Share/Bookmark

19
Dec 13

US Pharma Company Plans to Create 300 Jobs in Limerick

The 11.88 hectare sit in the Raheen Business Park in Limerick was previously owned by DellA US pharmaceutical company is planning to build a new production plant in Limerick which will create 300 highly skilled jobs over the next three years.

Regeneron Pharmaceuticals is seeking planning permission to locate on a 12-hectare site, previously owned by PC giant Dell, in the Raheen Business Park.

The project, which is supported by the Department of Jobs through IDA Ireland, would represent a major jobs boost for the Mid-West region.

New-York based Regeneron is one of the fastest growing biopharmaceutical companies in the US, and develops medicines for a range of illnesses including eye diseases and colorectal cancer.

The IDA has been working to attract its business here for four years.

The company is seeking planning to build its $300 million (€270 million) facility on the site, which has been vacant since 2009.

The project would involve a major refurbishment of existing buildings on the site as well as the construction of a quality control laboratory, which would transform the site into a biopharmaceutical campus.

Read [+]

  • Facebook
  • Twitter
  • LinkedIn
  • Google Bookmarks
  • Share/Bookmark

28
Jul 13

Pharma firm’s Facility to Treat Rare Disorders Creates 50 jobs.

A niche pharmaceutical company, Alexion Pharmaceuticals, has announced that it will be creating 50 jobs in Ireland with the establishment of a new facility to treat ultra-rare disorders.

The company is expanding its global presence with the opening of a new office and laboratory facility in Dublin in conjunction with the company’s decision to establish a global supply chain facility in Ireland.

The Irish facility will supply soliris (eculizumab) to patients suffering with two severe and life-threatening ultra-rare disorders PNH and aHUS.

The company’s expanding Irish workforce will also manage the supply of additional Alexion medicines to patients following regulatory approvals for a series of anticipated launches of new therapies over the next several years.

Executive vice president and chief global operations officer at Alexion Stephen Squinto said the company had chosen Ireland for its new facilities due to the workforce. “Ireland’s government and universities have an unparalleled commitment and robust partnerships with regard to education and training for pharmaceutical manufacturing, quality assurance, quality control and supply logistics. For these reasons, as we continue to expand our global supply chain and quality team, we are very pleased to come to Ireland for its highly skilled and educated workforce,” he said.

Alexion is involved in the emerging biophama industry which is seen as being the next wave of medical development following the boom in synthetic drugs that saw Ireland benefit from a pharma boom in the 90s.

Read [+]

  • Facebook
  • Twitter
  • LinkedIn
  • Google Bookmarks
  • Share/Bookmark

12
Jul 13

New Jobs as Pfizer Invests.

Pfizer is a leading pharmaceutical company. (Photo : Reuters) A company restructuring in Pfizer’s two plants went underway as the pharmaceutical giant announced that a US$130 million investment is heading their way.

A large portion of the investment will be given to the Grange Castle plant. The placement, worth US$100 million, is set to create almost 250 construction jobs in the plant located in Dublin, Ireland. The remaining US$30 million will be invested in the Ringaskiddy factory in Cork.

According to the company, the investments should allow the new production and development of new medicine for Pfizer. The company’s wonder drugs Lipitor and Viagra have recently come off their respective patents.

Pfizer’s products that have come off patent posed problems for the pharmaceutical firm in the past. Due to this phenomenon, a total of 177 layoffs were made because of a much needed cost reduction measure. The Cork site was the worst hit by the patent release.

“I am determined to ensure that we build on such success and provide the opportunities for further growth in this sector and create the jobs we so badly need,” said Ireland’s Jobs Minister Richard Bruton.

Read [+]

  • Facebook
  • Twitter
  • LinkedIn
  • Google Bookmarks
  • Share/Bookmark

10
Jul 13

Irish Start-up Pharmapod on Mission to bring Pharmacies into the Digital Age.

Irish start-up Pharmapod on mission to bring pharmacies into the digital age

Irish start-up Pharmapod on mission to bring pharmacies into the digital age
Leonora O’Brien, founder, Pharmapod, and Jim Kee, pharmacist at Corr’s Pharmacy, Clare Hall Shopping Centre, Dublin. Image via Brendan Duffy

Leonora O’Brien is the founder of a new Irish cloud-based start-up called Pharmapod.

Having worked in the pharmaceutical industry for 16 years, O’Brien recently decided to follow the entrepreneurial path and set up her own business. Her new technology start-up is garnering notice in the digital entrepreneurship scene in both Ireland and abroad, as Pharmapod’s software aims to bring pharmacies into the digital age.

In recent weeks, Pharmapod has scooped numerous accolades, including the €5,000 prize fund at the Tech Entrepreneurs workshop in Dublin as part of the European Digital Agenda Assembly in June. Last week, O’Brien was named as a finalist in the global Cartier Women’s Initiative Awards – the first Irish woman ever to be nominated for such an international honour.

A pharmacist by trade, O’Brien said she decided to leave the industry and become an entrepreneur when she spotted a niche to change the way pharmacies interact with each other and, ultimately, with patients.

Launched in November 2012, Pharmapod aims to improve knowledge sharing amongst pharmacists. The software caters for both community and hospital pharmacies, and should prevent errors or medication-related incidents, she said.

Read [+]

  • Facebook
  • Twitter
  • LinkedIn
  • Google Bookmarks
  • Share/Bookmark

2
Jul 13

Pharma firms create research hub

By Jimmy Woulfe, Mid-West Correspondent

Jobs and Enterprise Minister Richard Bruton

Launching the Synthesis & Solid State Pharmaceutical Centre at the University of Limerick (UL) yesterday, Jobs and Enterprise Minister Richard Bruton said: “This centre is to turn good ideas into good jobs.

“The pharmaceutical sector is crucially important to Ireland and employs 60,000 people, it exports €50m of product and it is absolutely essential that we develop the new opportunities in this rapidly changing sector.”

The Government has invested €30m to super the new ‘think tank’, with a further €10m coming from the industries involved.

Up to 90 research jobs will be generated in third- level colleges which will feed into the centre at UL.

Mr Bruton said the UL centre will draw world-class researchers to help develop new products. It will also, he said, act as a magnet to attract new pharmaceutical companies here.

Mr Bruton said: “This centre will be a unique resource that the industry can tap into.

“We pride ourselves in being able to promote collaboration in a way that other countries haven’t. We are creating a new environment for promoting commercialisation of research. That’s the key.”

Ireland is home to eight of the world’s top 10 pharmaceutical companies and six of the top 10 ‘blockbuster’ drugs are now made here.

Professor Kieran Hodnett, scientific director of the new centre at UL, said they will research topics important to the manufacture of medicines.

Prof Hodnett said: “Of all the medicines manufactured in the world, some part of half of all those medicines are manufactured in this country.”

He said the new centre will strengthen the position of pharmaceutical companies based here by conducting shared research, which will make their operations here more efficient and cost effective.

Read [+]

  • Facebook
  • Twitter
  • LinkedIn
  • Google Bookmarks
  • Share/Bookmark

27
May 13

Booming Irish pharmaceutical sector sets sights on China.

DUBLIN – Ireland in recent years has become a hub for the world’s pharmaceutical industry. Now, looking to expand market in China, government officials and pharmaceutical firms are wooing China’s counterparts for burgeoning deals and closer relations.

Ireland has become a popular location for pharmaceutical and bioprocessing plants. Ireland is now the eighth largest producer of pharmaceuticals in the world. There’s nine out of the top 10 pharma companies in the world are based in Ireland and nearly 50 percent of Irish exports are in the pharma and healthcare area.

Irish officials and researchers said that with such a large market, China will play an important role in the future development of pharmaceuticals, adding that increased interaction between Ireland and China could prove to be mutually beneficial in this field.

“We have a growing relationship with China. I think it’s something we want to really underpin for the future. Industrial Development Agency (IDA) has had traditionally a big focus on the US and Europe as sources of foreign direct investment in the pharmaceutical space,” said Barry Heavey, head of life sciences of IDA, which is responsible for attracting foreign direct investment in Ireland.

“A number of companies that are here in Ireland are sourcing some of their active ingredients from China and we would see increased relationships between China and Ireland being an important part of our future,” Heavey said.

“I think we are certainly spending more time in the Chinese market and interacting with our colleagues in China and trying to identify opportunities for investment from China and Ireland’s reputation in the development and manufacturing of these products is really second to none,” he said.

Killian O’Driscoll, director of projects of Ireland’s National Institute for Bioprocessing Research & Training (NIBRT), said China is obviously a very large market who is beginning to develop a strong capacity within bio-pharma manufacturing.

Read [+]

  • Facebook
  • Twitter
  • LinkedIn
  • Google Bookmarks
  • Share/Bookmark

9
Apr 13

Novartis to establish business services centre in Dublin, creating about 100 jobs

Novartis, the world’s second-largest pharmaceutical company, is set to grow its presence in Ireland with a new regional business services centre in Dublin, creating about 100 jobs for the area.

The new business services centre will consolidate digital marketing, salesforce training and medical communications services for the company and opens this month in the existing Novartis campus in Beech Hill, Dublin, while preparations are made for another location.

Novartis conducted an extensive study of Europe to find the best location for its new centre. Dublin was the front-runner on account of having a highly educated workforce with extensive pharmaceutical experience and language proficiency, as well as high rankings for other factors, such as accessibility and cost.

“Novartis takes pride in continuing to create high quality jobs in Ireland, particularly given the current economic challenges,” said Loretto Callaghan, country president and CPO head of Novartis Ireland. “Dublin will benefit from the investment Novartis is making in the community with the opening of this new centre in addition to the two other Novartis locations in Ireland.”

Read [+]

  • Facebook
  • Twitter
  • LinkedIn
  • Google Bookmarks
  • Share/Bookmark

7
Jul 12

Eli Lilly Smiles on Ireland as New Product Launch Site

Lilly

Eli Lilly & Co. will make its Dunderrow campus in Kinsale, Ireland, the pharma giant’s main launch site for all new products, company Chairman, CEO, and President John Lechleiter has told Irish newspapers.

Lechleiter said the quality of Ireland’s workforce and government support justified the decision, which followed Lilly spending €500 million ($615.5 million) on the Kinsale facility over the past five years.

“We’ve had a very good relationship with the [Industrial Development Agency Ireland or] IDA over the years. We’ve had an excellent relationship with universities none more so than [University College Cork or] UCC, where we had joint research programs, sponsored post-doctoral students, done internships,” Lechleiter told the Irish Examiner.

In comments reported this morning by the Irish-American news website IrishCentral, Lechleiter said the quality of young graduates remained a compelling reason for the company to operate in Ireland rather than cheaper Asian nations. He also brushed aside concerns raised by ministers of Ireland’s cabinet in recent weeks that diminished enrollment figures in science, engineering, and math would bring to Ireland the same skill-set shortage as has been seen in the US and some other nations in as little as five years.

But while Lilly continues to smile on Ireland, Lechleiter warned of future potential problems, tied to pricing for the company’s medicines.

“Ireland’s attractiveness for the kind of investment that our industry makes is also going to be connected with our ability to have our products reimbursed and to have the products that all of our people work on here available to people in Ireland now. Right now we’re at a bit of an impasse as we try to get back to negotiations with the government to ensure that that can happen,” Lechleiter told IrishCentral.

Lechleiter added that workforce quality was the “most decisive factor” behind Lilly’s decision30 years ago to build a substantial presence in Ireland. Lilly has operated at Kinsale since 1981, creating a bulk manufacturing site focused on producing active pharmaceutical ingredients for drugs that include Alimta®, Evista®, Strattera®, and Zyprexa®.

On Feb. 27, Lilly joined with Irish officials in announcing a further expansion of the Kinsale campus with a new €330 million ($442 million) manufacturing plant, for which construction began a month later. The 240,000-square-foot plant, to be operational in late 2013, will lead to 300 construction jobs, followed by creation of 200 new jobs at the facility, bringing Lilly’s total employment in Ireland up to almost 1,000.

The plant is Lilly’s second to be built at Kinsale, in Ireland’s County Cork, within the past five years. A €300 million ($402 million) biopharmaceutical manufacturing and new product commercialization facility finished construction and came online in 2010.

Read [+]

  • Facebook
  • Twitter
  • LinkedIn
  • Google Bookmarks
  • Share/Bookmark